Glucagon Function: In-Depth Analysis of Its Application Scope in Peptide Therapy
Abstract: Glucagon, a 29-amino acid peptide, extends beyond glycemic rescue in peptide therapy. Its application scope now includes metabolic disorders and cardiac support, leveraging its role in hepatic glucose production. Market trends show a CAGR of 7.8% (2024-2030), driven by dual-action agonists. Leading brands (e.g., Novo Nordisk, Eli Lilly) dominate via superior stability and receptor selectivity. Technical advantages include rapid onset; drawbacks involve short half-life requiring formulation modifications (e.g., PEGylation). Product parameters vary by purity (>98%) and bioactivity. Industry analysis highlights stringent FDA/EMA certifications as key differentiators. Selection criteria prioritize lyophilized forms for stability and cold-chain logistics (2-8°C). The sector’s future hinges on multi-target peptide engineering and scalable GMP manufacturing.